ELBS’ vision is that liquid biopsy becomes an integral part of the clinical routine for the benefit of patients, with prior scientific validation through extensive and controlled multicenter clinical trials. IORS’ task will be to contribute to reducing the gap between numerous research publications and validation of biomarkers in clinical practice. Currently, at IORS liquid biopsy is used in molecular diagnostics of lung cancer (detection of EGFR mutations) in the Laboratory for Molecular Genetics at the Department of Experimental Oncology. The STEPUPIORS team hopes that through cooperation with ELBS, IORS will have the opportunity to contribute to the expansion of indications in which liquid biopsy can be used as a minimally invasive alternative to tissue biopsy in Serbia for other tumor localizations, such as cancers of the digestive system.
